Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II open-label single-center study of the clinical activity and safety of the braf-v600 inhibitor vemurafenib (zelboraf) in combination with the b-cell targeting antibody rituximab (mabthera) in previously treated patients with hairy cell leukemia (hcl) carrying the braf-v600e mutation

Next Previous
X
Search
Trial Profile

A Phase II open-label single-center study of the clinical activity and safety of the braf-v600 inhibitor vemurafenib (zelboraf) in combination with the b-cell targeting antibody rituximab (mabthera) in previously treated patients with hairy cell leukemia (hcl) carrying the braf-v600e mutation

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 May 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary) ; Vemurafenib (Primary)
  • Indications Hairy cell leukaemia
  • Focus Therapeutic Use

    • Most Recent Events

    • 13 May 2021 Primary endpoint (Complete response at the end of planned treatment) has been met, according to results published in The New England journal of medicine.
    • 13 May 2021 Status changed to completed, according to results published in the New England Journal of Medicine.
    • 13 May 2021 Results published in the New England Journal of Medicine.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top